Complex solution for Alzheimer´s disease therapy development from idea to real solution.
- Three different drug substances by now (Agora 1, Agora 2, Agora 3).
- Each of them different approach how to combat Alzheimer´s disease.
- Different Alzheimer’s disease pathways as targets for our drug candidates to minimize the failure.
|Phase||Primary goal||Dose||Patient monitor||Typical number of participants||Success rate|
|Preclinical||Testing of drug in non-human subjects, to gather information on efficacy, safety and pharmacokinetics||Unrestricted||Scientific researcher||Not applicable (in vitro and animal studies only)|
|Phase 1||Testing of drug on healthy volunteers for safety and pharmakokinetics||Starting at subtherapeutic dose, but with ascending to therpeutic levels||Clinical researcher||20–100 normal/ elderly healthy volunteers||Approx. 70%|
|Phase 2||Testing of drug on patients to assess safety / tolerability; first assesmaent of efficacy||Therapeutic dose||Clinical researcher||100–300 patients with specific diseases||Approx. 33%|
|Phase 3||Testing of drug on patients to assess efficacy and safety||Therapeutic dose||Clinical researcher and personal physician||300–3,000 patients with specific diseases||25–30%|